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hance therapeutic appropriateness in the treat-
ment of musculoskeletal and neuropathic pain. 
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Chronic pain, Recurrent chronic, Analgesics, Opi-
oids, Tapentadol.
Introduction 
Musculoskeletal pain is the leading cause of dis-
ability in the world, and chronic pain has a major 
impact on healthcare costs, direct and indirect1,2. 
The current understanding is that chronic pain 
should be considered as a specific neurological 
disease entity3. Specifically, pain chronification 
does not offer a protective function: pain progress-
es over time from a signal based on physiological 
alert mechanisms to a maladaptive response and 
then to a neurological disease, requiring proper 
pharmacological management4,5. This progression 
is the ultimate result of a process of functional and 
structural modifications of neurological structures 
due to neuroplasticity phenomena6,7. In more de-
tails, neuroplastic changes reflect the adaptive neu-
rophysiological processes occurring as the result of 
altered afferent stimuli, which include nociceptive 
and neuropathic transmission to the spinal, sub-
cortical and cortical areas6. Those stimuli may be 
initially beneficial; however, they may persist in 
a chronic state. Ultimately, neuroplastic changes 
within different areas of the central nervous sys-
tem (CNS) may occur, explaining the transition 
from acute to chronic pain conditions.
The structural modifications that occur in 
chronic pain are among the main reasons for the 
Abstract. – OBJECTIVE: Chronic pain is now 
recognized as a neural disease, which results 
from a maladaptive functional and structur-
al transformation process occurring over time. 
In its chronic phase, pain is not just a symp-
tom but also a disease entity. Therefore, pain 
must be properly addressed, as many patients 
still report unsatisfactory pain control despite 
on-going treatment. The selection of the thera-
py – taking into account the pathophysiological 
mechanisms of pain – and the right timing can 
result in a successful analgesic outcome. This 
review will present the functional and structural 
modifications leading to chronification of pain, 
focusing on the role of tapentadol in this setting.
MATERIALS AND METHODS: For inclusion 
in this review, research studies were retrieved 
via a keyword-based query of multiple databas-
es (MEDLINE, Embase, Cochrane). The search 
was last updated in November 2016; no limita-
tions were applied. 
RESULTS: Functional and structural abnor-
malities of the nervous system associated with 
pain chronification have been reported in sev-
eral conditions, including osteoarthritis, chron-
ic back pain, chronic pelvic pain and fibromyal-
gia. Correct identification and treatment of pain 
in recurrent/progressive stage is crucial to pre-
vent chronification and related changes in neu-
ral structures. Among analgesic drugs, tapen-
tadol, with its dual mechanism of action (opioid 
agonist and noradrenaline reuptake blocker), 
has recently resulted active in pain control at 
both central and spinal level. 
CONCLUSIONS: Tapentadol represents a suit-
able candidate for patients at early progressive 
stage of pain who have developed neuroplastici-
ty with modification of pain pathways. The avail-
ability of different doses of tapentadol may help 
clinicians to tailor treatment based on the indi-
vidual need of each patient, with the aim to en-
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poor efficacy sometimes shown by analgesic ther-
apy8,9. Moreover, currently available analgesic op-
tions are not always applied in accordance with 
our growing understanding of the mechanisms 
underlying the etiology and chronification pro-
cess of pain10,11. Analgesic drugs targeting specif-
ic neuroplastic processes involved in pain chroni-
fication have been developed12-17.
Among them, tapentadol is characterized by a 
peculiar dual mode of action. This single molecule 
acts both as a µ-opioid receptor (MOR) agonist 
and as a norepinephrine reuptake inhibitor, there-
by generating synergistic analgesic action18. The 
availability of multiple dosages of tapentadol may 
allow its use in all the intermediate steps involved 
in the process of transition from acute to chronic 
pain. This review will present the functional and 
structural modifications leading to chronification 
of pain, with a focus on the role of tapentadol in 
this setting.
Search Criteria
For inclusion in this review, research stud-
ies were retrieved via a keyword-based query 
(e.g. “pain chronification”) of multiple database 
(MEDLINE, Embase, Cochrane). The search was 
last updated in November 2016; no limitations 
were applied. The abstract lists of major scientific 
congresses and the reference lists of the retrieved 
papers were also browsed. Papers were then con-
sidered for inclusion according to their relevance 
for the topic, as judged by the authors.
Pathophysiological Background
The standard classification of pain distinguish-
es between nociceptive pain (originating in tis-
sues in response to a nociceptor stimulation or 
nociceptive stimulus) and neuropathic pain origi-
nating in the peripheral nervous system (PNS) or 
CNS as a result of damage to nerve fibres. In both 
cases, nociceptive impulses (Figure 1) then trav-
el along A-delta fibres and C-fibres of first-order 
neurons (primary afferent fibres) and are trans-
mitted to second-order neurons residing in the 
spinal cord dorsal horn9,19-21. These neurons trans-
mit the pain impulse to the thalamus, where sub-
liminal perception of pain occurs, giving rise to a 
series of physiological modifications, such as hy-
pertension, tachycardia, and others. To enable the 
organism to locate the source of the pain stimu-
lus, third-order neurons project impulses received 
from second-order neurons to the cerebral cortex. 
Figure 1. Ascending and descending pathways involved in pain transmission and modulation (modified from3).
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However, the transmission of noxious stimuli 
along the ascending pathways is conditioned by 
the action of descending modulatory pathways, 
which, especially at the spinal level, may modify 
the intensity and characteristics of the perceived 
pain. At spinal synapses, the descending path-
ways promote the release of endogenous opioids, 
norepinephrine, serotonin (5-HT) and gamma- 
aminobutyric acid (GABA), which control the 
transmission between primary and secondary 
neurons22. 
Over the last years, mounting attention has 
been paid to the pathophysiological mechanism 
driving the shift from acute (i.e., physiological) 
to chronic (i.e., pathological) pain. This process 
of pain chronification is based first on functional 
changes and then encompasses structural alter-
ations of the CNS5.
Peripheral and Central Sensitisation
From an early stage (few hours) the neural 
structures involved in acute inflammatory pain 
start to undergo plastic modifications. This leads 
to peripheral sensitisation, in which peripheral 
nociceptors reduce their activation threshold and 
increase their responsivity to noxious stimuli. If 
the cause of the inflammatory pain resolves in a 
short period (a few days), the plastic modifications 
also regress23. However, if the stimulus persists, 
high-frequency transmission is upheld with mas-
sive release of glutamates and neuro-modulating 
peptides, ultimately leading to modifications of 
spino-thalamic neurons and interneurons, a phe-
nomenon known as central sensitisation. Central 
sensitisation may then involve other supraspinal 
integration structures such as the thalamus and 
cortex and constitutes the basis for chronifica-
tion of pain24. These short-term modifications are 
of a functional nature (e.g. recruitment of silent 
synapses and synaptic reinforcement) and are re-
versible. On the other hand, structural plasticity 
phenomena follow over time (sprouting/shrinking 
of fibres, neuronal death), and they are difficult to 
reverse25. 
In some types of musculoskeletal pain, for in-
stance, the process is based on an inflammatory 
nociceptive input. The initial excitation and pe-
ripheral sensitisation of nociceptors associated 
with tissue damage may produce a nociceptive 
input to the central systems that would be suffi-
cient to cause central sensitisation of neurons in 
the dorsal horn and/or at higher levels26. In such a 
context, persistence of the peripheral nociceptive 
input in combination with initial reduction in the 
efficacy of some inhibitory systems such as the 
GABAergic systems may result in chronification.
Descending Pathways in the 
Modulation of Pain 
Descending modulatory pathways – both fa-
cilitatory and inhibitory – originating in the su-
praspinal centers, influence the perception of pain 
and modulate the activity of nociceptors at the 
level of the spinal cord dorsal horns through an 
increase or decrease in the propagation of signals 
to the brain27. The action of neurotransmitters, 
including endogenous opioids, norepinephrine 
and serotonin, underlies the modulation of the 
noxious stimulus. In particular, MOR agonists di-
rectly influence and inhibit transmission of pain 
signals along the ascending pathways and, in ad-
dition, are involved in the modulation of supraspi-
nal pain signals through their action at the level 
of descending pathways5,9,22. While noradrenergic 
pathways have an inhibitory effect on the trans-
mission of pain, which also continues in case of 
neuropathic pain or chronic pain28, serotonin may 
also have a facilitatory effect particularly in the 
advanced stages of chronicity and is, therefore, 
pro-nociceptive29. An imbalance between ampli-
fied ascending signals and inadequate activation 
of the descending inhibitory pathway seems to 
underlie the development and maintenance of 
many chronic pain syndromes (Figure 2). Animal 
studies also suggest that effective involvement 
of the inhibitory descending pathways protects 
against the development of chronic pain30. More-
over, other studies in animal models demonstrate 
that µ-opioid receptor agonism is particularly rel-
evant in acute nociceptive pain, while the inhibi-
tory activity of noradrenaline reuptake is import-
ant in chronic neuropathic pain31.
Clinical Evidence 
The functional and structural modifications 
of the nervous system in response to pain have 
an immediate clinical relevance. The diagnosis 
of chronic pain in a patient with active chroni-
fication and neuroplasticity phenomena should 
not rely only on the duration of symptoms alone. 
Thus, chronic pain is more than just “pain that 
has lasted for 3 or 6 months”. Chronic pain32,33 
is defined according to three main features: (i) 
widespread pain which is diffused beyond the site 
of the primary lesion and does not necessarily fol-
low innervation territories; (ii) pathological pain 
(mixed, nociceptive and neuropathic pain) which 
has lost its physiological protective function; and 
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(iii) loss of response to the so-called “simple an-
algesics” (non-steroid anti-inflammatory drugs 
-NSAIDs- and paracetamol), since the chronifica-
tion process has involved superior structures of 
the CNS and has lost its immediate association 
with inflammation. An algorithm for the classifi-
cation of central sensitization pain has been pro-
posed based on the above-definitions (Figure 3)33.
The presence of functional and structural ab-
normalities of the nervous system and their clini-
cal relevance has been shown in some conditions, 
including osteoarthritis (OA), chronic back pain 
(CBP), chronic pelvic pain (CPP), and fibromyal-
gia (FMS).
Osteoarthritis
Patients with OA show some sensory abnor-
malities including widespread loss of cutaneous 
vibration sensitivity, hypoesthesia to punctate 
mechanical, pinprick and thermal stimuli and 
mechanical allodynia32. Also, pain in areas of 
their body and skin becomes referred and does 
not match the innervation territories of peripheral 
nerves or nerve roots. 
This referred pain in OA is mediated by cen-
tral sensitization nociceptors, continuously firing 
(ectopically) in and around the affected joint. The 
central sensitization in patients with OA has been 
supported by some studies34-36. As a further con-
firmation of pain sensitisation in OA patients, a 
meta-analysis of 15 studies pooled data on pres-
sure pain threshold (PPT) and heat pain threshold 
(HPT)37. The point estimate was large for differ-
ences in PPTs between knee OA participants and 
controls [-0.85; confidence interval (CI): -1.1 to 
-0.6], and moderate for PPT differences between 
knee OA participants with high symptom severi-
ty vs. those with low symptom severity (0.51; CI: 
-0.73 to -0.30). A small point estimate was also re-
ported for differences in HPTs between knee OA 
Figure 2. Pain chronification is the result of an imbalance between enhanced ascending nociceptive inputs and inadequate 
inhibitory descending system.
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participants and controls (-0.42; CI: -0.87 to 0.02). 
Moreover, in a very recent cross-sectional study, 
53 people with knee OA scheduled to undergo 
primary total knee arthroplasty were studied38. 
Pain frequency maps revealed enlarged areas of 
pain, especially in women; in particular, enlarged 
areas of pain were associated with higher knee 
pain severity (rs = 0.325, p <0.05) and stiffness 
(rs = 0.341, p <0.05), lower pressure pain thresh-
olds at the knee (rs = -0.306, p <0.05) and epicon-
dyle (rs = -0.308, p <0.05), and higher scores with 
the Central Sensitization Inventory (rs = 0.456, 
p <0.01). The authors of this study concluded 
that expanded distribution of pain was correlat-
ed with some measures of chronic sensitization 
in individuals with knee OA. Recently, increased 
pain sensitivity distantly from the knee reflects 
widespread hyperalgesia, thus further supporting 
chronic sensitization in patients with knee OA.
At a physiological level, animal models of OA 
have shown that ectopic sprouting of sensory and 
sympathetic nerve fibers occurs in the painful ar-
thritic joint and may be involved in the generation 
and maintenance of arthritic pain. Understanding 
the factors that drive this neuroplasticity, whether 
this pathologic reorganization of nerve fibers con-
tributes to chronic joint pain, and how the phenotype 
of sensory and sympathetic nerves changes with age 
may provide insight into better pharmacologic tar-
gets for controlling aging-related joint pain39,40.
Chronic Back Pain
Central sensitization leading to chronic pain 
plays a major role also in CBP, and it is associated 
with major structural alterations also at CNS. Ap-
karian et al41 compared brain morphology of 26 
CBP patients to matched controls. Patients with 
CBP showed 5-11% less neocortical gray matter 
volume than controls; by way of comparison, the 
magnitude of this decrease is equivalent to the 
gray matter volume lost in 10-20 years of normal 
aging. The decreased volume was also related to 
pain duration, indicating a 1.3 cm3 loss of gray 
matter for every year of chronic pain. Moreover, 
gray matter density was reduced in bilateral dor-
solateral prefrontal cortex and right thalamus and 
was strongly related to pain characteristics in a 
pattern distinct for neuropathic and non-neuro-
pathic CBP. These results imply that CBP is ac-
companied by brain atrophy and suggest that the 
pathophysiology of chronic pain includes thalam-
ocortical processes. 
In a more recent research, Fritz et al42 investi-
gated the association of CBP and regional gray 
matter volume in 111 individuals with CBP and 
432 pain-free controls, accounting for effects of 
medication. CBP was associated with decreased 
regional gray matter in the ventrolateral prefron-
tal cortex (PFC) and dorsolateral PFC, both the 
ventral and dorsal medial PFC, and the anterior 
insula. Pain intensity showed a weak negative 
correlation with gray matter volume in the left 
dorsolateral PFC, ventro-lateral PFC, and anterior 
cingulate cortex. The CBP sample showed alter-
ations in regions commonly associated with pain 
processing and emotional demands. 
Noteworthy, treating chronic pain can restore 
normal brain function: Seminowicz et al43 ac-
quired magnetic resonance imaging (MRI) scans 
from chronic CBP patients before (n = 18) and 6 
Figure 3. Algorithm for the classification of musculoskeletal pain (modified from33).
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months after (spine surgery or facet joint injec-
tions; n = 14) treatment. The control group includ-
ed 16 controls. After treatment, patients had in-
creased cortical thickness in the left dorsolateral 
PFC. Increased thickness correlated with the re-
duction of both pain and physical disability. Addi-
tionally, increased thickness in the primary motor 
cortex was associated specifically with reduced 
physical disability, and the right anterior insula 
was associated specifically with reduced pain. 
Left PFC activity during an attention-demanding 
cognitive task was abnormal before treatment, but 
following normalized treatment.
Chronic Pelvic Pain
In women with CPP, central changes similar 
to those identified in other pain conditions have 
been documented44. Specifically, these include al-
terations in the behavioral and central response 
to noxious stimulation, changes in brain struc-
ture (both increases and decreases in the volume 
of specific brain regions), altered activity of both 
the hypothalamic-pituitary-adrenal axis and the 
autonomic nervous system (ANS) and psycholog-
ical distress. The presence of these changes has 
the potential to both exacerbate symptoms and to 
predispose these women to the development of 
additional chronic conditions.  In more details, 
As-Saine et al45 applied voxel-based morphome-
try to determine whether women with CPP and 
with and without endometriosis display chang-
es in brain morphology in regions known to be 
involved in pain processing. Four subgroups of 
women participated: 17 with endometriosis and 
CPP, 15 with endometriosis without CPP, 6 with 
CPP without endometriosis, and 23 healthy con-
trols. Compared with controls, women with en-
dometriosis-associated CPP displayed decreased 
gray matter volume in brain regions involved in 
pain perception, including the left thalamus, left 
cingulate gyrus, right putamen, and right insu-
la. Women with CPP without endometriosis also 
showed decreases in gray matter volume in the 
left thalamus. Such decreases were not observed 
in patients with endometriosis who did not have 
CPP. Therefore, it is possible to conclude that CPP 
is associated with changes in regional gray matter 
volume. Given that dysmenorrhea is often a pre-
stage of CPP, these data suggest that pain chron-
ification is marked by a decrease in regional gray 
matter volume in the pain system. On the other 
hand, those women who remain relatively “pain-
free” do not show these decreases. In contrast, 
they show an increase in gray matter volume in 
the antinociceptive system, which might be adap-
tive. These findings support the use of adjunctive 
medication targeting the CNS in these women. 
Fibromyalgia
Similar findings were also reported for patients 
with fibromyalgia. Kuckinald et al46 investigated 
anatomical changes in the brain associated with 
fibromyalgia. In a study of 10 female fibromyal-
gia patients and 10 healthy controls, fibromyalgia 
patients had significantly less total gray matter 
volume and showed a 3.3 times greater age-asso-
ciated decrease in gray matter than healthy con-
trols. This means that each year of fibromyalgia 
is equivalent to 9.5 times the loss of gray matter 
associated with normal aging. Also, fibromyalgia 
patients demonstrated significantly less gray mat-
ter density than healthy controls in several brain 
regions. In a subsequent study of 25 fibromyal-
gia patients, 10 fibromyalgia patients with major 
depression (MD) and 35 healthy controls, fibro-
myalgia patients had lower pressure pain thresh-
olds than patients with MD and controls, and they 
reported higher pain intensity47. Upon unilateral 
pressure pain stimulation, increased bilateral 
cortical activation was revealed in fibromyalgia 
patients compared to controls. Fibromyalgia pa-
tients also displayed a stronger contralateral ac-
tivity over the dorsolateral PFC than patients with 
MD. These data provide further evidence for al-
tered central nervous processing in patients with 
fibromyalgia and the distinction between FMS 
and MD.
Clinical Features of Pain Chronification
According to available evidence, the process of 
chronification of pain can be divided into three 
consecutive stages. The first stage is character-
ized by the presence of acute, localized pain. In 
the second stage, the pain has not yet become 
chronic but it starts to change its characteristics 
in accordance with functional changes in neural 
structures. In the third and final stage, the pain 
has become a medical entity (Figure 4)2. Musculo-
skeletal pain for example starts out localized, then 
extends regionally and spreads more and more as 
time passes. In clinical practice, it is paramount 
to recognize each stage and establish appropriate 
treatment with the aim to prevent the progression 
of pain to a chronic state. 
Stage I: acute pain
A patient with initial musculoskeletal problems 
presents some time-limited episodes of localized 
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pain with intensity proportional to the lesion. The 
pain resolves with anti-inflammatory drugs. How-
ever, such episodes must not be underestimated or 
ignored given that even in the earliest stages, they 
may be sufficient to trigger the progressive stage. 
Stage II: progressive recurrent pain
The transition from acute pain to chronic pain 
is characterized by the onset of more intense ep-
isodes of pain. The interval between these epi-
sodes may be entirely pain-free or there may be 
mild persistent pain2. This stage is often char-
acterized by an increase in susceptible areas, a 
phenomenon that correlates directly with spinal 
sensitisation. This further highlights the impor-
tance of spinal phenomena in the chronification 
process22. The primary care physician has a major 
role in this initial stage, in which there is simul-
taneous progression of two diseases: the under-
lying musculoskeletal disease (osteoarthritis, for 
example) and the pain itself as a disease, which 
now can be defined as “recurrent”. The in-depth 
investigation of patient’s clinical history is cru-
cial. Pain in the recurrent stage tends to display 
some periodicity (e.g., monthly), typically lasts a 
relatively short time, and, in some cases, does not 
resolve completely between one episode and the 
next (persistence). The pain is probably still re-
sponsive to effective treatment, and therefore the 
initiation of appropriate therapy is paramount.
Stage III: chronic pain
Over time, the plastic modifications of the no-
ciceptive pathways lead to chronification of the 
pain. In this stage, the pain syndrome is consoli-
dated and well structured. The pain transmission 
and modulation pathways have now lost their 
physiological characteristics and have assumed 
some pathological properties. As the complexity 
increases, the disease becomes more difficult to 
control and stabilize. 
Selecting the Right Treatment
The selection of the proper analgesic treatment 
must take account of the clinical and subjective 
characteristics of the patient, and address at the 
same time the underlying pathogenic mecha-
nisms of the pain, including the neuroplasticity 
Figure 4. Progression of pain. Acute musculoskeletal pain starts out circumscribed, and then becomes chronic over time by 
developing from progressive/recurrent to chronic pain. From a clinical point of view, recurrent pain is characterized by re-
peated, localized and intense episodes of pain and development of changes in sensitivity (allodynia, hyperalgesia). In contrast, 
chronic pain is more diffuse and continuous, with the impairment of the patient’s mental and physical health. The severity of 
the lesion and the intensity of pain commonly lessen in this stage. Modified from2.
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processes which lead to chronification and trans-
formation of the symptoms, and which differ in 
the various stages involved in the progression of 
pain from symptom to disease (Table I). Also, 
a multimodal and multimechanistic approach 
to pain management must be considered. For 
instance, in the case of OA, treatment of pain 
should pursue three goals: inhibit peripheral 
mechanisms of pain and inflammation, treat cen-
tral pain mechanisms, and reduce progression of 
joint destruction (peripheral pain generators)48. 
While these goals were described for OA, they 
may also be applied to other conditions. Two 
basic criteria should be met when choosing the 
analgesic strategy: therapeutic appropriateness 
and timing. In particular, the selected drug must 
be capable of targeting the main mechanisms re-
sponsible for chronic pain, while tackling central 
sensitisation and controlling the nociceptive and 
neuropathic components4. According to these 
criteria, acute pain accompanied by an inflam-
matory phenomenon (post-traumatic inflamma-
tion, for example) arising from torn muscles, 
minor trauma or transient musculoskeletal pain 
can be treated by NSAIDs and paracetamol. 
Subsequently, in cases where the pain exhibits 
signs of progression (increase in susceptible ar-
eas, secondary allodynia), the use of NSAIDs is 
no longer sufficient because spinal sensitisation 
phenomena attributable to underlying functional 
plasticity are modifying the course of the pain 
disease. Furthermore, although appropriate in 
the presence of inflammatory pain, NSAIDs are 
not recommended for prolonged treatment be-
cause of the risk of adverse reactions, especially 
those involving the kidney, gastrointestinal tract, 
coagulation and cardiovascular systems, and are 
not suitable for treating neuropathic pain49-51. 
This stage of recurrent progressive pain is par-
ticularly important because its identification and 
treatment (which differs from acute treatment 
and should be continued for 3 or 4 weeks) may 
have a major impact on the natural course of the 
disease. Last, patients with moderate-to-severe 
chronic pain often require opioid analgesics for 
effective pain control7. On timing, the use of 
the right analgesic from the very initial stages 
of musculoskeletal pain can help prevent, slow 
down, and possibly reverse those pathological al-
terations leading to chronification and therefore 
prevent pain chronification and, in so doing, im-
prove the patient’s quality of life. Once the chron-
ic stage has been reached and the pain syndrome 
has stabilized, therapeutic intervention may no 
longer fully reverse the alterations in the nervous 
system. The modulation of the noradrenergic 
pathway using appropriate treatments may, in 
principle, be able to modulate neuropathic pain. 
To this end, the inhibition of serotonin and nor-
adrenaline reuptake has been proposed52,53. Also, 
nerve injury down-regulates MOR expression 
via an epigenetic mechanism54. The descending 
noradrenergic tone delays the appearance of ip-
silateral mechanical allodynia, cold allodynia, 
and heat hyperalgesia following nerve injury 
via an alpha 2-adrenoceptors mediated mecha-
nism30,55. In the spinal dorsal horn, noradrenaline 
released from descending pathways originating 
in the pontine A5-A7 cell groups attenuates pain 
by inhibitory action on alpha 2-adrenoceptors on 
central terminals of primary afferent nociceptors 
(presynaptic inhibition), by direct alpha 2-adren-
ergic action on spinal pain-relay neurons (post-
synaptic inhibition), and by alpha 1-adrenergic 
activation of inhibitory interneurons56. More-
over, alpha 2-adrenoceptors on axon terminals of 
Table I. Course of pain and appropriate treatments.
 Pathology (examples) Therapeutic options
Acute pain Torn muscles, minor trauma,  NSAIDs
(episodic and circumscribed) sprains, mild and transient  Paracetamol
 musculoskeletal pain Paracetamol in combination with weak opioids
Progressive recurrent pain  Early osteoarthritis, myalgia, Tapentadol PR 25 mg to 75 mg twice daily
(functional neuroplasticity) tension headaches, tendinitis,  Low-dose strong opioids + adjuvants
 arthritis  
Chronic pain Low back pain, osteoarthritis, Tapentadol PR 50 mg to 250 mg twice a day 
(structural neuroplasticity) fibromyalgia, cervicobrachialgia,  Full-dose strong opioids + adjuvants 
 radiculopathy, slipped disc, 
 spinal stenosis 
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excitatory interneurons might contribute to spi-
nal control of pain. At supraspinal levels, the ef-
fect of noradrenergic system on pain has varied 
depending on many factors such as the type of 
the adrenoceptor, pathophysiological condition, 
and the brain area. In general, the baseline pain 
sensitivity is only little influenced by the norad-
renergic system, whereas in injured conditions 
the noradrenergic system contributes to feed-
back inhibition of pain.
Tapentadol in the chronification of pain
Recent evidence demonstrating the importance 
of the descending noradrenergic pathways in the 
chronification processes suggests the usefulness 
of drugs with a targeted effect on norepineph-
rine reuptake to restore the equilibrium in the 
descending pathways. Drugs like tapentadol may 
act in this line by strengthening synaptic inhibi-
tion systems in the spinal cord and by preventing 
or eliminating some of the conditions resulting in 
the maladaptive plasticity of the synapses them-
selves57. A Cochrane Collaboration review on 
neuropathic pain reports that numerous studies 
demonstrate the superior efficacy of combining 
two different modes of action58. The reason for the 
poor efficacy of a drug with a single mechanism 
of action, especially for mixed types of pain, lies 
in the fact that nociceptive pain and neuropathic 
pain do not arise from the same pathogenic mech-
anisms and therefore require different therapeu-
tic approaches59. Thanks to its dual mechanism 
of action – MOR agonism and norepinephrine 
reuptake inhibition – tapentadol is an important 
therapeutic option which differs from classical 
opioids such as morphine and oxycodone: while 
its analgesic efficacy is similar to that of oth-
er strong opioids, it has considerably fewer side 
effects57, including lower potential of abuse60,61. 
This favorable efficacy/safety profile may be at-
tributed, at least in part, to the synergic effect of 
the two analgesic mechanisms, which enables the 
use of an opioid with lower affinity for µ-opioid 
receptors (about 50-fold lower than morphine), in 
turn reducing the risk of side effects, notably gas-
trointestinal. Moreover, tapentadol has a low risk 
of drug interactions, and for that reason may be 
particularly suitable for the treatment of patients 
on multiple medications. Interestingly, tapentadol 
does not behave as morphine during a chronic 
treatment: it is, in fact, able to induce internal-
ization of µ-opioid receptors, whereas morphine 
does not, therefore suggesting a different molec-
ular mechanism at receptor level62. Tapentadol 
activity both on the central and spinal level has 
recently been demonstrated, which also makes 
the drug a suitable candidate for patients who 
have developed neuroplasticity that has modified 
pain pathways and rendered traditional analge-
sic therapies ineffective. In a randomized trial, 
diabetes patients who interrupted tapentadol af-
ter titration maintained a lower intensity of pain 
compared with baseline values; those who con-
tinued tapentadol experienced a further reduction 
of pain intensity63. Similar findings were reported 
by another study64. Niesters et al57 analyzed 24 
patients with diabetic polyneuropathy (DPN) who 
were randomized to receive daily treatment with 
tapentadol sustained-release (SR) [average daily 
dose 433 (31) mg] or placebo for 4 weeks. Condi-
tional pain modulation (CPM) and offset analge-
sia were measured before and on the last day of 
treatment57. Before treatment, none of the patients 
had significant CPM. At week 4 of treatment, 
CPM was significantly activated by tapentadol SR 
and coincided with significant analgesic respons-
es. CPM increased from 9.1 ±5.4% (baseline) to 
14.3 ±7.2% (placebo) and 24.2 ±7.7% (tapentadol 
SR, p <0.001 vs. placebo); relief of DPN pain was 
also greater in patients treated with tapentadol 
than placebo (p = 0.028). Tapentadol analgesic ef-
fect in chronic pain patients with DPN appeared, 
therefore, dependent on activation of descending 
inhibitory pain pathways as observed by CPM 
responses. This dosage and duration of treatment 
should take advantage of the two mechanisms of 
action of the drug, i.e. in tackling the pain as a 
symptom and intervening in the neuroplastic pro-
cesses responsible for chronification. Given these 
premises, tapentadol at doses of 50 mg to 250 mg 
twice daily (BID) may be helpful to treat severe 
chronic pain65, the ideal median dosage being 150 
mg BID for at least three months.
Conclusions
Continuing advances in our understanding 
of the pathophysiological mechanisms underly-
ing pain have revealed the importance of central 
mechanisms. In particular, a stage of initial pro-
gression has now been identified. This is import-
ant because intervention at this point with drugs 
like tapentadol – appropriate from the point of 
view of its two mechanisms of action and the 
availability of low doses – can have an impact 
on the neuroplastic transformations leading to 
chronification, by blocking or at least slowing 
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down those processes. The availability of a wide 
range of doses – including the recent addition of 
a 25 mg formulation – enables clinicians to ad-
just treatment to suit the needs of the patient and 
the characteristics of the pain in the individual 
case. The range of choices available helps maxi-
mize therapeutic appropriateness both in the ini-
tial stages of chronification and in the long-term 
treatment of the main forms of chronic musculo-
skeletal pain (such as osteoarthritis and lumbago) 
and neuropathic pain.
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